|
Help | |
You are here: Rediff Home » India » Business » Special » Features |
Discuss this article | Email this article | Print this article Bright spots in a grim market |
|
Advertisement | ||
| ||
There seems to be no stopping for the market correction now. So is it the right time to buy? Are valuations cheaper now? Experts have the answers.
With the market on a slide yet again is it the right time to buy? Are valuations looking cheaper at this point?
Experts reveal this as well as the sectors that are looking good.
Investment advisor P N Vijay: FMCG looking strong
In terms of performance, I think FMCG continues to be very strong. This is due to the strong numbers of the leading players on the back of the pricing power. A lot of expansion and consolidation is taking place. Even midcap companies like Emami are getting larger. FMCG is one space that is really interesting, it is a total domestic play and that is worth watching.
Construction sector also looking good
The construction sector is right in the middle of this economic investment cycle, so shares like Nagarjuna, IVRCL and L&T would benefit from falling commodity prices also. Both these sectors are here for superior gains in the medium term.
Gautam Shah of J M Morgan Stanley: Capital goods, auto to be hit more, banking, pharma to outperform
Most of the sectors are looking weak on the charts and just about every sector is going to be hit. But capital goods and autos, which have run up quite substantially in the last few months are likely to be worst hit. Watch for these two sectors on the sell side and we have covered a lot of stocks on the sell side in these two sides.
Apart from these two banking might just outperform in this market because it has already reacted last week and this is a one sector, which has a positive technical setup from medium term and long-term perspective.
Also pharmaceuticals because the pharmas stocks have not run up too much in the recent past, so they might just be stable in case the market weakens. Watch for banking and pharmaceuticals from an outperformance perspective.For more such reports, long on to www.moneycontrol.com
Email this Article Print this Article |
|
© 2006 Rediff.com India Limited. All Rights Reserved. Disclaimer | Feedback |